Dyne Therapeutics, Inc. (DYN)
After hours:
| Previous close | 35.38 |
| Open | 35.66 |
| Bid | 32.45 x 100 |
| Ask | 32.62 x 200 |
| Day's range | 32.14 - 35.98 |
| 52-week range | 6.40 - 35.98 |
| Volume | |
| Avg. volume | 1,318,114 |
| Market cap | 2.851B |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
- Benzinga
Why Is Dyne Therapeutics Stock Soaring On Monday?
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Earlier this year, Dyne Therapeutics released initial clinical data from both trials. In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseli
- Investor's Business Daily
Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again
Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.
